BGLC vs RMD · rev $99.0K vs P/E 29, rev $5.65B
BioNexus Gene Lab Corp Common stock (BGLC) versus ResMed Inc (RMD) — a side-by-side from cached financials, not a winner call.
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
ResMed Inc (RMD) is a medical instruments & supplies company listed on US.
Latest reported BGLC revenue for 2026-06-30 was $99.0K. Net income was -$830.0K. BGLC currently screens at market cap $6.1M.
Latest reported RMD revenue for 2026-06-30 was $5.65B. Net income was $1.52B. Revenue was up 9.9% from 2025-06-30 to 2026-06-30. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
BGLC currently screens at market cap $6.1M. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
Not investment advice. Open the BGLC and RMD stock pages for the full models.
Not investment advice.